Referral to the Women s Alcohol and Drug Service (WADS) Procedure

Similar documents
Referral to the Women s Alcohol and Drug Service (WADS) Procedure

Health Care Worker (Pregnant) - Infectious Diseases Risks and Exposure

Thalassaemia and Abnormal Haemoglobins in Pregnancy

Magnesium Sulphate - Management of Hypertensive Disorders of Pregnancy

Neonatal Abstinence Syndrome Questions & Answers Webinar #1 (February 9, 2012) Webinar #2 (March 30, 3012)

Workplace Drug and Alcohol Policy

Managing drug misuse in pregnancy and beyond

The Aboriginal Maternal and Infant Health Service: a decade of achievement in the health of women and babies in NSW

PROCEDURES AND GUIDANCE

HA Corporate Scholarship Program:

Drugs cross the placenta producing a new set of pharmacokinetics.

NHS FORTH VALLEY LOCAL ENHANCED SERVICE (2010) General Practitioner Prescribing Service (GPPS) Opiate Assisted Treatment Service Specification

Buprenorphine & Controlled Substance Treatment Agreement

Alberta Alcohol and Drug Abuse Commission. POSITION ON ADDICTION AND MENTAL HEALTH February 2007

Opioid Substitution Treatment in Christchurch

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

The pointy end of the stick

Surveillance report Published: 8 June 2017 nice.org.uk. NICE All rights reserved.

Effects of Prenatal Illicit Drug. Use on Infant and Child

Prepublication Requirements

Drug and Alcohol Policy

The Opioid-Exposed Woman

Maternal-fetal Opiate Medical Home (MOMH) Jocelyn Davis DNP,CNM, RN, CEFMM Karen Frantz BSN, RNC

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION

Workplace Drug and Alcohol Policy

Clinical Guidelines and Procedures for the Use of Naltrexone in the Management of Opioid Dependence Abbreviated Version

NHS Grampian Tobacco Policy 2016

FASD Prevention and Health Promotion Resources

Matrix Framework of PERINATAL DEPRESSION and RELATED DISORDERS

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Learning Objectives. Serving Pregnant Women Affected by Substance Use Disorders in Healing to Wellness Court: Sharing Lessons

NIDAC Online Consultation 1: Alcohol. Summary of Findings

The Woodlands Managing Alcohol To Support Recovery In Mental Health

Child Welfare and MOMS: Building Partnerships to Improve Care

22 April 2002 Central Australian Aboriginal Congress Submission: Taskforce on Illicit Drugs

Smoking cessation in pregnancy guideline for practice (GL917)

Protecting Vulnerable Groups Guidance for Care Inspectorate staff and service providers Publication date: October 2012

PATIENT GROUP DIRECTION

PREGNANCY SERVICES WORKING IN PARTNERSHIP TO REDUCE INEQUALITIES & REDUCE THE PREVALENCE OF SMOKING IN PREGNANCY

Casual AOD Clinician: Assessment, Care & Recovery and Counselling

Brief History of Methadone Maintenance Treatment

Interdisciplinary Management of Opioid Use Disorder in Rural Primary Care Settings

DRUGS, ALCOHOL & MENTAL HEALTH, HOW THEY CONNECT

Substance-Exposed Newborn

Trigger. Myths About the Use of Medication in Recovery BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS

WELCOME TO THE CRACKS IN THE ICE WEBINAR SERIES

in pregnancy Document Review History Version Review Date Reviewed By Approved By

Virginia. Prescribing and Dispensing Profile. Research current through November 2015.

Substance Misuse in Older People

POLICY AND GUIDANCE FOR MANAGERS ON STAFF SUBSTANCE MISUSE

SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE

THE IMPACT OF SUBSTANCE USE

Pathway to wellness. What is perinatal anxiety and depression? Post & Ante Natal Depression Support & Information Inc.

HIV ANTENATAL TESTING IN AUSTRALIA AFAO BRIEFING PAPER February 2001

2/24/2017. Pregnant Women Who Use Drugs: Stigma, Science and Society

NHS public health functions agreement Service specification No.1 Neonatal hepatitis B immunisation programme

Non-Pharmacologic Treatment for Infants with Neonatal Abstinence Syndrome (NAS)

Appendix 1: Data elements included in the AODTS NMDS for

Specialist Perinatal Mental Health Service (SPMHS)

Service Level Agreement for the Provision of Level 1 Substance Misuse Services from a Community Pharmacy under contract to NHS Grampian

The transition to parenthood, mood changes, postnatal depression and post traumatic stress disorder

Statistics from the Northern Ireland Drug Misuse Database: 1 April March 2012

COMPLETE DRUG AND ALCOHOL POLICY & Testing Policy

Pioneering, addiction medicine, wrap-around service

WOMEN AND OPIOIDS Media Guide

ATOP. Australian Treatment Outcome Profile. Presented by Lan Wu & Elly Staunton-McKenzie. Special Thanks to Alan Gude & Linda Hipper

4/19/2018. Opioid Use Disorder in Pregnancy OBJECTIVES ANTENATAL TESTING

UNIVERSITY STATEMENT FOR STUDENTS ON SUBSTANCE USE/MISUSE

Updated Activity Work Plan : Drug and Alcohol Treatment NEPEAN BLUE MOUNTAINS PHN

Community alcohol detoxification in primary care

The 5A's are practice guidelines on tobacco use prevention and cessation treatment (4):

Women & Children's Business Unit Maternity Contraception and Sexual Health

Gestational Diabetes Mellitus (GDM) and Diabetes in Pregnancy: Diagnostic Recommendations, NSLHD

Product Labeling to Communicate Benefits and Risks of Treatment for Opioid Use Disorder in Pregnant Women. Hendrée E. Jones, PhD

Medication-Assisted Treatment. What Is It and Why Do We Use It?

Primary Health Networks

Supervisor Handbook for the Diploma of Diagnostic Ultrasound (DDU)

Important Information

Talking with your doctor

Statistics from the Northern Ireland Drug Misuse Database: 1 April March 2011

APPLICATION FOR Page 1/8 RESIDENTIAL TREATMENT

Drug related hospital stays in Australia

PSYCHOTROPIC MEDICATION UTILIZATION PARAMETERS FOR CHILDREN AND YOUTH IN FOSTER CARE

Associates of Behavioral Health Northwest CHILD/ADOLESCENT PSYCHOSOCIAL ASSESSMENT

Mental Health and AoD Community Briefing Outcomes

FY17 SCOPE OF WORK TEMPLATE. Name of Program/Services: Medication-Assisted Treatment: Buprenorphine

Disclosures. Objectives 2/5/2018. Women and opioid use disorder: Optimizing care during pregnancy and beyond

Mental health services. Fairfield & Liverpool. December 2008

TTC Evidence Brief: Evidence for Maternal Mental Health within World Vision Core Health Model Timed and Targeted Counselling (ttc)

FPA Sri Lanka Policy: Men and Sexual and Reproductive Health

NHS public health functions agreement

Consultation Group: Dr Amalia Mayo, Paediatric Consultant. Review Date: March Uncontrolled when printed. Version 2. Executive Sign-Off

Marijuana in the Obstetric Population

Smoking cessation interventions and services


Maternal and Child Health, Substance Abuse Ohio Department of Health, Bureau of Maternal Child and Family Health

Implementation guide. Pandemic flu kit

for adults engaged with the Family Wellbeing Service Isle of Wight In Community Pharmacy for Isle of Wight Public Health Commissioned Services

Appendix C. Aneurin Bevan Health Board. Smoke Free Environment Policy

Transcription:

Procedure Referral to the Women s Alcohol and Drug Service (WADS) Procedure. Purpose The following document describes criteria for the referral to Women s Alcohol and Drug Service (WADS) and how a referral is taken and processed. This includes the referral for clinical care and secondary consultations. 2. Definitions Women s Alcohol and Drug Service (WADS): The Women s Alcohol and Drug Service (WADS) provides specialist clinical services and professional support in the care of pregnant women with complex substance use and alcohol dependence. It utilises a multidisciplinary team approach to advance their health and well-being and the medical needs of their infants. In addition to clinical care, WADS provides assessments, training, clinical practice guidelines, secondary consultation and support to other maternity hospitals caring for pregnant women with drug and alcohol use, mentoring and secondary consultations to health professionals around Victoria. Screening: A screening is undertaken to identify women who are likely to require more extensive assessment. The screening will identify women at risk and where outcomes can be improved by early intervention. Important considerations in a screening are: Nature and circumstances of alcohol and drug use Pregnancy factors Immediate risks for self-harm Past and present mental health disorders Past and present history of trauma and violence. Assessment: Assessment is a process of identifying the nature and scope of the problem and determining specific treatment recommendations. An assessment will examine a woman s life in greater detail to ensure an accurate understanding of her drug and/or alcohol use, her experiences of physical, psychological harm and socio-economic history to determine specific treatment plans. Assessment is not a once off event. Rather it is a fluid process undertaken throughout the course of treatment and care. An assessment will only be undertaken if a woman has been accepted into WADS care. Secondary Consultations: Secondary consultations concern the provision of clinical advice and support to health and community professionals at their request. In a secondary consultation, patients may be seen. 3. Responsibilities All clinical staff involved in the care of mothers and babies must be familiar with the procedure for referral to WADS. Teamcare Coordinators and Social Workers are responsible for booking patients in for screenings by WADS. Uncontrolled document when printed Published: (/02/209) Page of 9

Procedure Referral to the Women s Alcohol and Drug Service (WADS) Procedure 4. Procedure 4. Service WADS routinely care for women with complex substance use and alcohol dependence, medical, social and psychiatric conditions. WADS aims to build a strong therapeutic relationship with women to ensure that both mother and infant have the best health and social outcomes. The service is made up of the following specialties: Addiction Medicine Drug and Alcohol Counselling and Assessment Obstetric Care Midwifery Care Paediatric Care Assessing and Caring for babies with Neonatal Abstinence Syndrome Infant Home Based Withdrawal Program Methadone Stabilisation Program Mental Health Assessment Nutritional Care Pharmaceutical Advice and Assessment. 4.2 Criteria for Referrals Referrals can either be self-referred, or referred by family, friends, community or health organisations or other service providers. Referrals are assessed under the following criteria in the Antenatal Period: Commencement of opiate substitution therapy/ treatment Alteration of opiate substitution therapy treatment Assistance with alcohol withdrawal and treatment Assistance with cannabis withdrawal/use and treatment Assistance with amphetamine withdrawal/use and treatment Assistance with benzodiazepine withdrawal/use and treatment Assistance with pain management in women with substance use Limited or no-antenatal care. Refer to : Complex alcohol and drug use criteria 4.3 Procedure for Referrals A referral must be faxed to WADS. When a referral is received, a screening will be undertaken within a 24 hour period by WADS. Contact is made with the referrer and the woman being referred to assess suitability. Following the screening, if the woman is assessed as appropriate for WADS, she will be booked in for assessment and a pregnancy booking. Uncontrolled document when printed Published: (/02/209) Page 2 of 9

Procedure Referral to the Women s Alcohol and Drug Service (WADS) Procedure If the woman is suitable for care in Teamcare, contact will be made with the relevant referrer and a referral faxed to the Teamcare coordinator and social worker. If the woman is out of geographical location she will referred to her local maternity hospital for management and care. Refer to Appendix 2: Women s Alcohol and Drug Service (WADS) Referral Flowchart. Refer to medical record number: OP/20 for the Internal Referral form. Screenings will also be undertaken for women who present in the postnatal period. 4.4 Criteria for Secondary Consultations Secondary consultation is the key to WADS service provision and support to RWH staff and external service providers. Criteria for secondary consultations include: Brief intervention/ education/ information Commence medication Pain management in women with substance use Withdrawal management Smoking cessation Advice regarding post discharge follow up Advice post alcohol withdrawal Peri-operative advice Delirium associated with substance use Any concerns about a pregnant woman s current use of prescribed and unprescribed substances of dependence. 5. Evaluation, monitoring and reporting of compliance to this guideline Not yet developed. 6. References. Drug and Alcohol Office, NSW Health. National clinical guidelines for the management of drug use during pregnancy birth and for the newborn. Sydney 2006. www.health.nsw.gov.au/pubs/2006/ncg_druguse.html 2. Cochrane Database of Systematic Reviews. Randomized controlled trials enrolling opiate dependent pregnant women: Cochrane Database of Systematic Reviews. 2008; (2): (CD00638) 3. Australian Government Department of Health and Ageing. Clinical Guidelines and Procedures for the use of Buprenorphine in the Treatment of Heroin Dependence. 2006. http://www.nationaldrugstrategy.gov.au/internet/drugstrategy/publishing.nsf/content/buprenorphineguide 4. NH&MRC. Australian Guidelines to Reduce Health Risks from Drinking Alcohol. NH&MRC Reference No: DS0, 2009. http://www.nhmrc.gov.au/publications/synopses/ds0syn.htm Uncontrolled document when printed Published: (/02/209) Page 3 of 9

Procedure Referral to the Women s Alcohol and Drug Service (WADS) Procedure 7. Legislation/Regulations related to this guideline Not applicable. 8. Appendices : Complex alcohol and drug use criteria Appendix 2: Women s Alcohol and Drug Service (WADS) Referral Flowchart Please ensure that you adhere to the below disclaimer: PGP Disclaimer Statement The Royal Women's Hospital Clinical Guidelines present statements of 'Best Practice' based on thorough evaluation of evidence and are intended for health professionals only. For practitioners outside the Women s this material is made available in good faith as a resource for use by health professionals to draw on in developing their own protocols, guided by published medical evidence. In doing so, practitioners should themselves be familiar with the literature and make their own interpretations of it. Whilst appreciable care has been taken in the preparation of clinical guidelines which appear on this web page, the Royal Women's Hospital provides these as a service only and does not warrant the accuracy of these guidelines. Any representation implied or expressed concerning the efficacy, appropriateness or suitability of any treatment or product is expressly negated In view of the possibility of human error and / or advances in medical knowledge, the Royal Women's Hospital cannot and does not warrant that the information contained in the guidelines is in every respect accurate or complete. Accordingly, the Royal Women's Hospital will not be held responsible or liable for any errors or omissions that may be found in any of the information at this site. You are encouraged to consult other sources in order to confirm the information contained in any of the guidelines and, in the event that medical treatment is required, to take professional, expert advice from a legally qualified and appropriately experienced medical practitioner. NOTE: Care should be taken when printing any clinical guideline from this site. Updates to these guidelines will take place as necessary. It is therefore advised that regular visits to this site will be needed to access the most current version of these guidelines. Uncontrolled document when printed Published: (/02/209) Page 4 of 9

Complex alcohol and drug use criteria Complex alcohol and drug use criteria: This document outlines criteria for complex alcohol and drug use, factors relevant in a psychological assessment determining levels of risk and complexity. This document provides a chart that can be used by staff to assist in their decision making of where a woman is best placed for her care. Complex alcohol and drug use: yes = No: 0 Score Poly drug use (current) Presents as substance affected at appointment Denies drug use but presents as in withdrawal or affected by drugs Recent heavy i and regular ii use of a single drug or multiple drugs A strong desire or sense of compulsion to take the substance Impaired capacity to control substance-taking behaviour iii Dependent on alcohol or other drugs- unable to function without the drug iv Evidence of tolerance to the effects of the substance, such that there is a need for significantly increased amounts of the substance to achieve intoxication or the desired effect Patient withdraws when ceases using substance (s) v Patient requires medication and ongoing assessment by addiction medicine in WADS service to manage withdrawal symptoms and drug use vi Preoccupation with substance use, as manifested by important alternative pleasures or interests being given up or reduced because of substance use vii Patient has entrenched drug using regular use over a period of years viii Patient is on a high dose of methadone >00mg methadone Patient is nearing maximum dose of buprenorphine >32mg at 20 weeks into pregnancy Previous attendance to WADS clinic Total score: Complex psychosocial circumstance and identification of risk: In addition to assessment of complex drug use, the worker will also assess the patient s psychological well-being, social context and circumstances. This will involve identifying and assessing indicators of risk, including mental health and Uncontrolled document when printed Published: (/02/209) Page 5 of 9

Complex alcohol and drug use criteria emotional well-being and vulnerability to violence. The following indicators combined with complex drug use indicate that a referral to WADS is recommended. Psychosocial risks Score Financial difficulty / Poverty Diagnosis of one or more psychiatric disorder Risk of self-harming behaviour History of trauma Instability of housing Limited or no family or social support Vulnerability to the violence s of others ix Forensic history, including recent incarceration History of child protection with self or older children Children out of care Family members using AOD Violent history towards others and / or capacity to harm others Lack of attendance and/ or engagement in care Poor historian/ Lack of disclosure Total score A score of five or more in the category of complex alcohol and drug use in conjunction with a score of five or more in psychosocial risks indicates need for WADS management. Non-complex Drug use: Patients identified as having less risk factors in both their drug use and their social functioning can be cared for via team care and managed through secondary consultation. The following factors can assist in determining non-complex drug use. Use of a single drug only over a short or extended period of time (for e.g. Cannabis) Irregular or non- recent drug use No or limited withdrawal on cessation of substances Limited psychological and physical harm associated with the drug use Strength in social functioning, including relationships with family and significant others and in meeting basic needs Does not spend long periods drug seeking. Requires minimal medical consultation and management around AOD use or withdrawal Uncontrolled document when printed Published: (/02/209) Page 6 of 9

Complex alcohol and drug use criteria Majority of pregnancy care has been in team care Engaged with Social work and/or social work is a good source of information and support Engaged with external psychosocial supports Heavy use relates to daily use, IV drug use. Periods of binging for 2-3 days. Patient is unable to engage in other activities. The patient spends long periods of time drug seeking. Patient experiences physical and psychological symptoms of withdrawal. Regular drug use is defined as daily use or use that occurs at a set time each week In terms of its onset, termination, or levels of use, as evidenced by the substance being often taken in larger amounts or over a longer period than intended https://www.psychology.org.au/assets/files/perspectives-substance-use.pdf It s important not to be confused with the symptoms of a withdrawal state. For e.g. a 'hangover' is not necessarily an indicator or severe of dependent use Physical symptoms vary according to the substance being used. Psychological disturbances (e.g. anxiety, depression, and sleep disorders) are also common features of withdrawal. Typically, the patient is likely to report that withdrawal symptoms are relieved by further substance use. See CPG s in relation methadone stabilisation, alcohol and cannabis dependence in pregnancy and methamphetamine dependence in pregnancy http://www.who.int/substance_abuse/terminology/definition/en/ Entrenched drug use relates to a patient that uses regularly and psychosocial circumstances are affected by the ongoing use. The patient is not able to do without the drug, engages in regular drug seeking behaviour and experiences withdrawal symptoms if not using the drug. http://www.who.int/substance_abuse/terminology/definition/en/ Uncontrolled document when printed Published: (/02/209) Page 7 of 9

Women s Alcohol and Drug Service (WADS) Referral Flowchart Women s Alcohol and Drug Service (WADS) Referral Flowchart Women with current or a history of substance use, or on methadone or buprenophine and/ or late antenatal presentation Fax referral to WADS 8345 2996 WADS to complete screening of referral WADS screening Check if stable on pharmacotherapy No current substance use No complex psychosocial issues Presented for pregnancy care under 20/40 Current substance use/ high pharmacotherapy dose WADS referral to Teamcare WADS to fax referral and WADS screening to the Team Coordinator and Social Worker WADS care Note: If changes in situation; poor attendance; lapses in substance use: Contact WADS Duty worker: 8345 393 for additional screening WADS to fax Teamcare coordinator & inform Uncontrolled document when printed Published: (/02/209) Page 8 of 9

Women s Alcohol and Drug Service (WADS) Referral Flowchart i Heavy use relates to daily use, IV drug use. Periods of binging for 2-3 days. Patient is unable to engage in other activities. The patient spends long periods of time drug seeking. Patient experiences physical and psychological symptoms of withdrawal. ii Regular drug use is defined as daily use or use that occurs at a set time each week iii In terms of its onset, termination, or levels of use, as evidenced by the substance being often taken in larger amounts or over a longer period than intended iv https://www.psychology.org.au/assets/files/perspectives-substance-use.pdf v It s important not to be confused with the symptoms of a withdrawal state. For e.g. a 'hangover' is not necessarily an indicator or severe of dependent use vi Physical symptoms vary according to the substance being used. Psychological disturbances (e.g. anxiety, depression, and sleep disorders) are also common features of withdrawal. Typically, the patient is likely to report that withdrawal symptoms are relieved by further substance use. See CPG s in relation methadone stabilisation, alcohol and cannabis dependence in pregnancy and methamphetamine dependence in pregnancy vii http://www.who.int/substance_abuse/terminology/definition/en/ viii Entrenched drug use relates to a patient that uses regularly and psychosocial circumstances are affected by the ongoing use. The patient is not able to do without the drug, engages in regular drug seeking behaviour and experiences withdrawal symptoms if not using the drug. ix http://www.who.int/substance_abuse/terminology/definition/en/ Uncontrolled document when printed Published: (/02/209) Page 9 of 9